Address: Na Pankráci 1683/127 140 00 Praha 4,Czech Republic
Tel: +420 255 706 200
Web: http://www.biogenidec.cz/
Biogen Idec is a Fortune 500 company and global biotechnology leader that generates more than $5 billion in annual revenues. Our mission is to discover, develop and deliver innovative therapies for the treatment of neurodegenerative diseases, hemophilia, and immunology to patients worldwide through cutting-edge science and medicine. Our robust product pipeline is supported by one of the industry’s leading capacities for biologics manufacturing, featuring nearly 200,000 liters of bioreactor capacity.
We have more than 5,000 employees worldwide and a direct commercial presence in more than 29 markets and a network of distribution partners in more than 70 additional markets, including emerging markets such as Central and Eastern Europe, Brazil, China and India. We pursue our mission through a strategic combination of internal research and development and through partnerships, alliances, and acquisitions.
With an unshakeable commitment to our mission and values, we expect to build shareholder value by bringing meaningful therapies to patients with serious, unmet medical needs.
Biogen Idec has had an affiliate in the Czech market since 2006.
Today, Biogen Idec is the oldest independent biotechnology company in the world. Patients worldwide benefit every day from its industry leading multiple sclerosis (MS) products. The company’s R&D efforts are focused on bringing new therapies to market for patients with neurodegenerative diseases, autoimmune disorders and hemophilia.
Ms. Hrdličková, can you please begin by introducing yourself to our readers, and providing a brief overview of your pharmaceutical career? My educational background is in general and molecular biology,…
The latest pharma news from Central and Eastern Europe (CEE), including a new report on the disparities between the region’s healthcare systems and those of Western Europe; why US companies…
Roman Grunt, CEO of Quinta Analytica, gives us an overview of the activities of how the Czech firm has managed to attract customers across the country and beyond by positioning…
PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: Czech Republic is available for download now. Home to a USD 3.38 billion pharma market, one of Central and Eastern Europe’s…
Key stakeholders within the Czech medtech industry highlight how medical devices can improve efficiency and quality of care across the country’s healthcare landscape, why greater levels of collaboration are of…
Roman Samiec, general manager of Thuasne Czech Republic, introduces the company as a key competitor in the medical devices field, with their niche products addressing the unmet medical need in…
Miroslav Palát, president of CzechMed, the medical device association in the Czech Republic, and Jiří Pavlíček, who combines the responsibility of Chairman of the association and CEO of the medtech…
Pavla Nevolová, country head of EastHORN in the Czech Republic, shares the historical roots of the now multinational Czech CRO. Nevolová also shares her insights into the recent evolution of…
The Czech Republic boasts a solid clinical research infrastructure and a supportive regulatory environment, meaning that it stands out as one of Central and Eastern Europe’s top destinations for clinical…
In 1996 Jiří Žák, chairman & current CEO of FARMAK, borrowed half a billion Czech crowns to take over a state-owned producer of vitamins for which he had started working…
As one of the few pharma companies in the Czech Republic to offer products across the whole healthcare spectrum, including prescription drugs, generics, over-the-counter (OTC) treatments, and food supplements, the…
Roman Dusil, GM of Pierre Fabre Laboratories in the Czech Republic and Slovakia, shares how the Czech affiliate is ahead of Pierre Fabre’s global transformation of the convergence between the dermo-cosmetic…
Pharma industry stakeholders are generally quick to suggest that the Czech Republic is one of the most over-regulated markets in Europe, with new or innovative therapies facing significant delays before…
See our Cookie Privacy Policy Here